Ranok Therapeutics Expands Clinical Testing of CHAMP® BRD4 Protein Degrader RNK05047 to China
Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers, today announced the initiation of patient dosing in China for a Phase 1 study of RNK05047, its first protein degrader candidate.
- Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancers, today announced the initiation of patient dosing in China for a Phase 1 study of RNK05047, its first protein degrader candidate.
- Ranok anticipates preliminary data from both the US and China Phase 1 studies by the end of 2024.
- “RNK05047, which has been developed using Ranok’s proprietary CHAMP® technology, is the first BRD4-selective protein degrader to have entered clinical testing in China.
- “RNK05047 degrades BRD4 protein preferentially in tumors, which may potentially lead to improved safety and efficacy.